Is mode of breast cancer detection associated with cancer treatment in the United States?

Cancer

Volumn 112, Issue 5, 2008, Pages 1011-1019

  Yabroff, K Robin ^a   Harlan, Linda C ^a   Clegg, Limin X ^a,b   Ballard Barbash, Rachel ^a   Stevens, Jennifer ^c   Weaver, Donald L ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer detection; Breast cancer detection; Chemotherapy; Mammography; Practice guidelines; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; AUTHOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL STUDY; COMPREHENSION; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; DEMOGRAPHY; FEMALE; HEALTH CARE; HOSPITAL; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SAMPLE; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HOSPITAL BED CAPACITY; HOSPITALS, PRIVATE; HUMANS; MAMMOGRAPHY; MASTECTOMY; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 39749102271     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23260     Document Type: Article

References (35)

1. Coates RJ, Uhler RJ, Brogan DJ, et al. Patterns and predictors of the breast cancer detection methods in women under 45 years of age. Cancer Causes Control. 2001;12:431-442.
2. Joensuu H, Lehtimaki T, Holli K, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA. 2004;292:1064-1073.
3. Moody-Ayers SY, Wells CK, Feinstein AR. "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med. 2000;160:1109-1115.
4. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 1999;91:2020-2028.
5. Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst. 2000;92:743-749.
6. Shen Y, Yang Y, Inoue LYT, Munsell M, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005;97:1195-1203.
7. Senie RT, Lesser M, Kinne DW, Rosen PP. Method of tumor detection influences disease-free survival of women with breast carcinoma. Cancer. 1994;73:1666-1672.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
9. Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
10. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
11. Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst. 2001;93:1704-1713.
12. Makuc DM, Breen N, Freid V. Low income, race, and the use of mammography. Health Serv Res. 1999;34(1 pt 2):229-239.
13. Smith-Bindman R, Miglioretti DL, Lurie N, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med. 2006;144:541-553.
14. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94:490-496.
15. Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessler LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Educ. 1996;88:716-726.
16. Boyd C, Zhang-Salomons JY, Groome PA, Mackillop WJ. Associations between community income and cancer survival in Ontario, Canada and the United States. J Clin Oncol. 1999;17:2244-2255.
17. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994;272:947-954.
18. Ries LAG, Eisner MS, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2002. Bethesda, Md: National Cancer Institute; 2005.
19. Fleming ID, Cooper JS, Hensen DE, eds. AJCC Cancer Staging Manual, 5th ed. Philadelphia, Pa: Lippincott-Raven; 1998.
20. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347-360.
21. Breen N, Yabroff KR, Meissner HI. What proportion of breast cancers are detected by mammography in the United States? Cancer Detect Prev 2007;31:220-224.
22. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol. 2006;24:872-877.
23. Charlson ME, Pompei P, Ales KL., MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
24. Carlson RW, Goldsetin LJ, Gradishar WK, et al. Update of the NCCN guidelines for treatment of breast cancer. Oncology. 1997;11:199-220.
25. National Institutes of Health. Adjuvant Therapy for Breast Cancer. NIH Consensus Statement 2000 November 1-3. Bethesda, Md: National Institutes of Health; 2000.
26. SAS Institute Inc. SAS/STAT User's Guide, 4th ed, version 6. Cary, NC: SAS Institute Inc.; 1989.
27. Enger SM, Thwin SS, Buist DSM, et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol. 2006;24:4377-4383.
28. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
29. Nemoto T, Natarajan N, Smart CR, Mettlin C, Murphy GP. Patterns of breast cancer detection in the United States. J Surg Oncol. 1982;21:183-188.
30. Conway BJ, Suleiman OH, Rueter FG, Antonsen RG, Slayton RJ. National survey of mammography facilities in 1985, 1988, and 1992. Radiology. 1994;191:323-330.
31. Hendrick RE, Chrvala C, Plott CM, Cutter GR, Jessop NW, Wilcox-Buchalla P. Improvement in mammography quality control: 1987-1995. Radiology. 1998;207:663-668.
32. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20:1809-1817.
33. Aiello EJ, Buist DS, Wagner EH, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2007 [Epub ahead of print].
34. Carlson RW, Anderson BO, Bensigner W, et al. Update: NCCN practice guidelines for the treatment of breast cancer. Oncology. 1999;13(5A):41-66.
35. Characteristics of the SEER population compared with the total United States population. 2006. Available at URL: http://seer.cancer.gov/registries/ characteristics.html Accessed on December 18, 2007.